Calcium Channel Blocker Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Calcium Channel Blocker Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Calcium Channel Blocker Market is expected to register a CAGR of 5.1 % during the forecast period (2022-2027).

The pandemic had a significant effect on the market growth. For instance, the research study titled "Anxiety, home blood pressure monitoring, and cardiovascular events among older hypertension patients during the COVID-19 pandemic" published in January 2022 reported that anxiety related to the COVID-19 pandemic is linked to a temporary rise in the home morning sleep blood pressure (SBP) among older patients and increases the risk of cardiovascular events over the course of the 1-year follow-up. As a result, continuous blood pressure monitoring is necessary both during and after the pandemic, which will spur the market for calcium channel blockers to rise over the future years in order to maintain blood pressure stability among the diagnosed population. Additionally, a number of projects involving blood pressure are starting in 2020 in order to improve and support blood pressure. For example, the American Heart Association received USD 32 million in December 2020 through a series of cooperative agreements with the United States Department of Health and Human Services for a national initiative to improve COVID-19-related health outcomes by reducing high blood pressure among racial and ethnic populations, who have higher rates of high blood pressure and are at increased risk for COVID-19 and severe chronic conditions such as heart disease. Thus, the market had an adverse effect at the initial stage of the pandemic however, the market will grow in the future.

The increasing prevalence rate of cardiovascular diseases and changing lifestyle of people are expected to boost the calcium channel blocker market growth. Various research studies have been published to provide insight about the calcium channel blockers. For instance, according to a research study published in May 2022 titled "Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer," calcium channel blockers (CCBs) like amlodipine significantly increased the therapeutic responses to gemcitabine in orthotopic xenografts and transgenic models of pancreatic ductal adenocarcinoma by inhibiting prosurvival epidermal growth factor receptor (EGFR) signalling in vitro (PDAC). Hypertension often referred as elevated blood pressure is one of the major causes associated with heart diseases. Increasing heart disease is another factor in market growth. For instance, according to a news release issued by Boehringer Ingelheim GmbH in August 2021, heart failure is a chronic, incapacitating cardio-renal-metabolic disease that affects about 60 million individuals or more worldwide. As the prevalence of heart failure continues to rise, new therapeutic options are desperately needed. As a result, there was a global demand for the pharmaceuticals available to treat hypertension, which fueled the rise of the market under investigation. Thus, the abovementioned factors are expected to increase the market growth.

However, product recalls in recent years may hinder the market growth.

Key Market TrendsHospitals Segment is Expected to Hold a Major Share in the Calcium Channel Blocker Market

A hospital also referred to as a medical center, is a health care institution providing patient treatment with specialized medical and nursing staff and medical equipment. Factors such as increasing cases of hypertension along with an increasing number of hospitals and initiatives by the public organization are expected to increase the market growth. For instance, according to the American Hospital Association, 2021, the total number of all United States Hospitals was 6,090 in number. More than 700 million individuals around the world have untreated hypertension, according to data updated by the World Health Organization (WHO) in August 2021, and 1.28 billion people worldwide have hypertension as of that year, a sharp increase over the previous few decades. Additionally, hypertension considerably raises the risk of renal, heart, and brain problems, according to the WHO publication. As a result, there is an increase in demand for medications used to manage hypertension, which is anticipated to propel the segment's expansion. In the Indian state of Andhra Pradesh, Medicover Global opened a 250-bed hospital in February 2020 and promised to extend it by building a 100-bed cancer treatment facility, the Medicover Oncology Institute (MOI). According to its plan to expand in India, the corporation has already invested around 700 crore rupees there and plans to add another 300 crores in the near future. Such an investment will bring in more patients, and as most treatments depend on stable blood pressure, this will spur market expansion. Thus, the abovemention factors are likely to increase the market growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global calcium Channel blocker market due to changing lifestyles among people and the increasing prevalence rate of cardiovascular diseases. The adoption of a sedentary lifestyle has serious implications on the health of people and is known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. Furthermore, according to the Pan American Health Organization (PAHO) for 2021, ischemic heart disease and stroke are the leading causes of mortality and significant factor in disability in the Americas. Cardiovascular diseases (CVD) are also one of the main causes of death and disability worldwide. According to the same source, ischemic heart disease is a significant cause of 73.6 fatalities per 100,000 people. In the Americas, 40.8 million disability-adjusted life years (DALYs) are caused each year by cardiovascular illnesses. Thus, to prevent such high mortality the adoption of hypertension prevention drugs is expected to increase. This is expected to increase market growth in the upcoming future. Due to the significant incidence of obesity in the United States, obesity is also one of the main causes of high blood pressure. Mexico formally endorsed the HEARTS project in February 2020. The Pan American Health Organization/World Health Organization (PAHO/WHO) is supporting the effort, which aims to improve primary care-level hypertension prevention and management. The goal is to reduce the burden of chronic diseases and get closer to achieving the Sustainable Development Goals by 2030. Such a program is probably going to increase the need for blood pressure medications in the nation, which will help to fuel the rising need for calcium channel blockers. Similar to this, the Canadian Hypertension Congress took place in Canada in 2020 from September 24 to September 26. To speed up innovation, Congress encourages networking and collaboration between providers and professionals in the health care industry. Thus, the abovementioned factors are expected to increase the market growth.

Competitive Landscape

The Calcium Channel Blocker Market is fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc, Alvogen, Abbvie Inc, Exela, Pharma Sciences, LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, Arbor Pharmaceuticals LLC among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.